Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial.
about
Granulocyte colony-stimulating factor activating HIF-1alpha acts synergistically with erythropoietin to promote tissue plasticityGranulocyte and granulocyte-macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic syndromesErythropoietin or darbepoetin for patients with cancerErythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient dataErythropoietin or Darbepoetin for patients with cancerEpigenetic approaches in the treatment of myelodysplastic syndromes: clinical utility of azacitidineManagement of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project.The role of lenalidomide in the management of myelodysplasia with del 5q.Is there a role for all-trans retinoic acid in combination with recombinant erythropoetin in myelodysplastic syndromes? A report on 59 cases.NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes.Current therapy of myelodysplastic syndromesp-ERK1/2 is a predictive factor of response to erythropoiesis-stimulating agents in low/int-1 myelodysplastic syndromes.Validation of disability status, a claims-based measure of functional status for cancer treatment and outcomes studiesMyelodysplastic syndrome and histone deacetylase inhibitors: "to be or not to be acetylated"?Feedback signals in myelodysplastic syndromes: increased self-renewal of the malignant clone suppresses normal hematopoiesis.Patient and physician characteristics associated with erythropoiesis-stimulating agent use in patients with myelodysplastic syndromes.Quality of life and physicians' perception in myelodysplastic syndromesThe role of rHuEpo in low-risk myelodysplastic syndrome patients.Emerging drugs for the treatment of myelodysplastic syndrome.Cost of the treatment of myelodisplastic syndrome in Brazil.The revolution of myelodysplastic syndromes.Efficacy of growth factors compared to other therapies for low-risk myelodysplastic syndromes.Exploring Erythropoietin and G-CSF Combination Therapy in Chronic Stroke Patients.Erythropoiesis-stimulating agents versus RBC transfusion in MDS: comparison of long-term outcomes.APG101 efficiently rescues erythropoiesis in lower risk myelodysplastic syndromes with severe impairment of hematopoiesis.Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes.Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996).Darbepoetin alfa in anemia of myelodysplastic syndromes: present and beyond.Myelodysplastic syndromes: clinical practice guidelines in oncology.Health-related quality of life and symptom assessment in patients with myelodysplastic syndromes.Review of therapeutic options and the management of patients with myelodysplastic syndromes.Update on the pharmacotherapy for myelodysplastic syndromes.Resuscitating a dying marrow: the role of hematopoietic growth factors.Iron overload in myelodysplastic syndromes (MDS) - diagnosis, management, and response criteria: a proposal of the Austrian MDS platformProspective international validation of the Quality of Life in Myelodysplasia Scale (QUALMS).Combined administration of alpha-erythropoietin and filgrastim can improve the outcome and cost balance of autologous stem cell transplantation in patients with lymphoproliferative disorders.Use of n-of-1 (single patient) trials to assess the effect of age of transfused blood on health-related quality of life in transfusion-dependent patients.High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM.
P2860
Q21136403-5D08D55A-FAFD-41AC-9D81-0869830A7F9BQ24186133-B3A348DA-43DD-4B2E-A431-79CA9A32B52DQ24202335-65B92785-915B-4D57-836B-A51E053F89AAQ24240202-F3A437AB-E3F8-447A-A597-01FC21E9AD52Q24245464-D281FCB2-285A-4351-AD58-FA9E05905F3FQ24608659-4091CC95-1DB5-4C08-BB68-41D1D64BB0A0Q30235355-F7CFFC42-F5E0-4E70-B351-101EF13670FCQ33373051-33052C0D-BC4C-4DEE-8407-EEDE0D039F30Q33378398-1128CC63-AC6A-4920-83B1-6753D6F11282Q33382828-167BFE23-24DB-4296-B7BC-CE97626F8C4BQ33393647-CFB70AFB-BC62-4F73-B2FF-CDA7AF910509Q34013796-E7073758-2342-4AE1-B454-4291E4740FF2Q34255198-C3D34C8A-BE41-4953-AA85-9C8D2CE04114Q34637063-C384A2F0-AE60-4256-811B-2A937A113CD2Q35001132-08500900-A481-4661-9A88-B38347E75049Q35156907-3DF40EA5-7AB7-4222-A8B9-51B66783CE15Q35643068-9F04A222-D2CC-4751-BA4C-4996DF3DC8EAQ36062056-E410E24C-FFFC-4B07-8629-BF8899FA4C17Q36194667-60EB1870-25C4-4E2B-954E-79A55A3D0A53Q36219655-486DBADF-AF01-42CC-9496-35ACF2439AF8Q36464326-5FD7E79B-0D85-4B48-8ACA-803824266E52Q36612553-5E6CE460-F150-4BDA-A49D-13CEA6B971D0Q36773010-E38594B4-E3F8-45A2-A4A6-32AD183B369CQ36846925-F9AA2FB7-881C-45EF-ADD6-CF36F31EF2CDQ36895801-F5AC4CA5-8E1A-4958-97FF-1EE0ABDA011BQ37046747-B0956B07-4C13-492E-AAE8-1869CD62CE69Q37125405-E89CBE1B-0C01-48F6-85D4-159308894B61Q37263146-17CFB327-9360-4B81-96F1-2198173EDFCDQ37352471-D6A7AB2C-96E2-4D38-9B7E-784C894AA4A0Q37702223-DE255B07-037E-4AF6-B441-D49094B52F19Q37723847-58B324F5-A1A2-4B26-B2DD-65BE8ECFE4B0Q37810109-8194068F-78DA-4980-828F-304AB08605F7Q38095121-D9BE5751-2BD9-496F-8C7E-198F19935839Q38235662-76F1648C-A58F-4023-945B-38FD26DE14B5Q38259813-73B59B6A-E235-4968-8AE4-68AC5A3E3475Q39529378-ADEB369C-8B7D-42C1-8D6D-A879BFE16EDBQ39947011-39A3D68A-A3D6-4BC1-9005-AF828A08D1E7Q40528386-03396D77-C4A8-427D-BBB5-A5FA5458C575Q40933609-2105F61B-4DB4-46C5-B9BE-5A4747FEF711Q45154727-61FF4B6C-9DC8-4571-A363-91600B003E16
P2860
Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Health, economic, and quality- ...... randomized, controlled trial.
@en
Health, economic, and quality- ...... randomized, controlled trial.
@nl
type
label
Health, economic, and quality- ...... randomized, controlled trial.
@en
Health, economic, and quality- ...... randomized, controlled trial.
@nl
prefLabel
Health, economic, and quality- ...... randomized, controlled trial.
@en
Health, economic, and quality- ...... randomized, controlled trial.
@nl
P2093
P50
P1433
P1476
Health, economic, and quality- ...... randomized, controlled trial.
@en
P2093
Agnès Guerci
Anne Vekhoff
Aspasia Stamatoullas
Eric Lepage
François Dreyfus
François Hemery
Frédéric Maloisel
Gandhi Damaj
Guy Laurent
Jean-Pierre Marie
P304
P356
10.1182/BLOOD-2003-07-2252
P407
P577
2004-03-30T00:00:00Z